Showing 7391-7400 of 8979 results for "".
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Denova Research and Illinois Dermatology Institute Partner for Clinical Researchhttps://practicaldermatology.com/news/denova-research-and-illinois-dermatology-institute-partner-for-clinical-research/2457894/DeNova Research is partnering with Illinois Dermatology Institute to become one of the largest and most comprehensive Dermatologic and Cosmetic Clinical Research sites in the Midwest. Denova Research has over 10 years’ experience, 110 publications and 76 clinical trials; many of whi
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for
- Research Finds Acne Linked with Increased Risk of Depressionhttps://practicaldermatology.com/news/research-finds-acne-linked-with-increased-risk-of-depression/2457898/In an analysis of one of the largest electronic medical records databases in the world, researchers found that patients with acne had a significantly increased risk of developing major depression, but only in the first 5 years after being diagnosed with acne.
- Short Course Radiation Best Longer Courses in Older Skin Cancer Patientshttps://practicaldermatology.com/news/short-case-radiation-best-longer-courses-in-older-skin-cancer-patients/2457899/Shorter courses of radiation seem to be better than longer ones for older patients receiving treatment for basal and squamous cell skin cancers, a recent Penn State College of Medicine physician’s st
- Seeing Scars: Patients and Doctors Often Disagree in Evaluating Surgical Scarringhttps://practicaldermatology.com/news/seeing-scars-patients-and-doctors-often-disagree-in-evaluating-surgical-scarring/2457902/Patients and doctors often don’t assess scar severity the same way, a new study in JAMA Facial and Plastic Surgery suggests. Researchers from the Perelman School of Medicine at the U
- eRelevance Adds Two to Executive Leadership Teamhttps://practicaldermatology.com/news/erelevance-adds-two-to-executive-leadership-team/2457901/eRelevance has added two new names to its executive leadership team. Rafael Landestoy is now vice president of business development and Travis Skidmore is vice president of client success and retention. Mr. Landestoy will lead eRelevance&nbs
- Apple Update Brings Healthcare Records to Phoneshttps://practicaldermatology.com/news/apple-update-brings-healthcare-records-to-phones/2457906/Apple has introduced a significant update to the Health app with the iOS 11.3 beta introducing a feature that gives customers access to their medical records on their iPhone. The updated H
- Amazon, Berkshire Hathaway, JPMorgan Chase Partner on Healthcarehttps://practicaldermatology.com/news/amazon-berkshire-hathaway-jpmorgan-chase-partner-on-healthcare/2457907/Amazon, Berkshire Hathaway, and JPMorgan Chase & Co. are partnering in an effort to seek solutions for delivering healthcare to their employees. The three companies will pursue this objective through an independent company that is free from profit-making incentives and constraints, they said
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d